anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
1,177,796. Hair spray lacquer. NATIONAL STARCH &amp; CHEMICAL CORP. 15 March, 1967 [18 March, 1966], No. 12207/67. Heading A5B. [Also in Divisions C2, C3 and C4] An aerosol composition for use as a hair spray lacquer comprises an organic solvent solution of an ultra-violet absorbing film-forming copolymer in admixture with a propellant therefor. The copolymer may be a copolymer of an ethylenically unsaturated derivative of phenyl salicylate, benzophenone, benzotriazole or a phenol (wherein the ethylenic unsaturation is ortho to the hydroxyl) with a vinyl ester; alkyl or hydroxyalkyl acrylate or methacrylate; acrylic, methacrylic, itaconic or crotonic acid; or an alkyl half-ester of maleic or fumaric acid. Co-polymers with vinyl esters may be partially hydrolysed. The preparation of many such copolymers having up to 5 monomers is described. The propellant may be trichlorofluoromethane, dichlorodifluoromethane, isobutane or propane or mixtures thereof. Optional ingredients include glycols, phthalate esters and glycerine plasticisers; silicones, lanolin, protein hydrolysates, ethylene oxide adducts and polyoxyethylene cholesterol.
A group B adenovirus comprising a sequence of formula 5&#39;ITR-B1-BA-B2-BX-BB-BY-B3-3&#39;ITR, wherein: By comprises a sequence -G1-G2n-G3m-G4p-G5q. G1 is a first transgene. G2 is a second transgene. G3 is a third transgene. G4 is a fourth transgene. G5 is a fifth transgene and IL-15 is encoded as a transgene in at least one of said locations, and characterised in that BY also encodes a polypeptide comprising the sushi domain of IL-15R alpha.
PURPOSE:To obtain a subject medicine consisting of a cyclic peptide having a specific amino acid sequence, having endothelin antagonism and useful for preventing and treating diseases in which endothelin participates, e.g. hypertension, cardiac infarction, arteriosclerosis or bronchial asthma. CONSTITUTION:Amino acid compounds whose alpha-amino groups are protected are successively bound from C end sides using a chloromethyl resin, etc., as an insoluble carrier by a solid synthesis of peptide to synthesize a linear peptide chain and the linear peptide is eliminated from the insoluble carrier. Then, the C end of the resultant linear peptide is converted into hydrazide and the hydrazide is induced into an azide and then converted to a cyclic peptide by a cyclizing azide method and the protecting group is removed to provide the objective cyclic peptide having endothelin antagonism and expressed by formula I {X&lt;1&gt; is DTrps; X&lt;2&gt; is DAsp, DGln, etc.; X&lt;3&gt; is formula II [A is 2-5C alkylene, etc., which surfur may be interposed; Y is OCO, COO, O, etc.; Q is (substituted)1-6C alkyl, etc.]; X&lt;4&gt; is DAla, DVal, etc; X&lt;5&gt; is (substituted)Ala, Val, Lun, etc.}.
PROBLEM TO BE SOLVED: To prepare a granule useful for a hygroscopic and water-soluble product, especially for a medicine or a treating agent, etc., for cultivated plants by carrying out the fluidized bed granulation while controlling the granule humidity of the product. SOLUTION: This hygroscopic and water-soluble product granule 1 having 200-2,000μm average grain diameter is prepared by bonding each of plural particle 2 having 5-200μm average particle diameter with solid bridges 3 of a solidified hygroscopic product and coating the surface of each particle 2 with the solid bridges 3. That is, each particle 2 becomes an aggregate coated with a hygroscopic product (e.g. sodium bentazon as an agrochemical). The resultant granule 1 has a compact and nearly spherical shape and further a cavity 4 and pore spaces 5 capable of manifesting capillary actions. Furthermore, the granule 1 is prepared by heating an aqueous solution containing 20-70wt.% hygroscopic and water-soluble product, spraying the heated solution on a fluidized bed opposite to the flow of a fluidizing gas and carrying out the fluidized bed granulation.  The product moisture in the granule 1 is regulated so as not to be &gt;=50% based on the residual moisture in the final product granule 1.
A composition for diagnosing neurodegenerative diseases is provided to diagnose diseases related to memory loss including Alzheimer&#39;s disease by applying clinical proteomics to cerebrospinal fluid focusing on quantitative change of a protein biomolecule relating to the progress of the disease. A composition for diagnosing neurodegenerative diseases such as Alzheimer&#39;s disease comprises at least one protein selected from the group consisting of a fibrinogen gamma-A chain precursor including an amino acid sequence described in SEQ ID : NO. 1, a retinol binding protein including an amino acid sequence described in SEQ ID : NO. 2, and a haptoglobin precursor allyl 1 including an amino acid sequence described in SEQ ID : NO. 3. A method for diagnosing neurodegenerative diseases comprises the steps of: (a) measuring a level of a fibrinogen gamma-A chain precursor from a test sample obtained from a patient; and (b) comparing a level of a fibrinogen gamma-A chain precursor obtained from a normal sample with the level obtained from the step(a) and diagnosing the neurodegenerative diseases when the level of the test sample is high.
This invention is directed to improved catalytic compounds, hammerhead ribozymes, capable of hybridizing with a target RNA to be cleaved. These improved compounds have optimized stems (X)m * (X)m&#39;, loops (X)b and hybridizing arms. The invention is also directed to compositions for enhanced RNA cleavage which comprise a first synthetic non-naturally occurring oligonucleotide compound which comprises nucleotides whose sequence defines a conserved catalytic region and nucleotides whose sequence is capable of hybridizing with a predetermined target sequence and a second synthetic non-naturally occurring oligonucleotide which does not contain the predetermined target sequence and is complementary to at least a portion of the first oligonucleotide compound. The invention is also directed to synthetic non-naturally occurring oligonucleotide compounds embedded in a tRNA. The ribozymes and compositions of the present invention may be used in vitro or in vivo. They may be used as diagnostic or therapeutic agents.
A class of predominantly hydrophobic monomeric or dimeric non-azo N-substituted 1,8-naphthalimide compounds, each bearing, at its 3-position, a nucleofuge and, at its 4-position, a heteroatomic electron-releasing group. A preferred embodiment is a &#34;monomeric&#34; non-azo N-substituted-l,8-naphthalimide compound bearing, at a 3-position, a nucleofuge and, at a 4-position, a heteroatomic electron-releasing group, which is being characterized as having a heteroatom directly linked to the 4-position and having at least one hydrogen directly attached to the heteroatom. An additional embodiment is a predominantly hydrophobic &#34;dimeric&#34; non-azo bis-naphthalimide compound, having at least two 1,8-naphthalimide moieties each bearing, at a 3-positon, a nucleofuge and, at a 4-position, a heteroatomic electron-releasing group which is being characterized as having a heteroatom directly linked to the 4-position and having at least one hydrogen directly attached to the heteroatom. The bis-naphthalimide compound is further characterized as giving an activated derivative after being activated by a sufficient amount of activating agent in an environment independent of the presence or absence of oxygen. The activated species initiate chemical changes in lipid bilayer membranes of viruses and other target cells. These changes can eradicate viruses and other target cells. The activated species can also cause structural changes in lipid and any associated proteins and polypeptides at a level beneath the surface of the membrane, leading to polymerization and crosslinking.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new compound having an antitumor activity and an inhibitory activity for cell motility and to provide a method for producing the same and an antitumor agent and a cell motility inhibitor comprising the same as an active ingredient and a new microorganism having the ability to produce the compound.  &lt;P&gt;SOLUTION: The compound is represented by general formula (I). The method for producing the compound comprises culturing the microorganism belonging to the genus Aspergillus and having the ability to produce the compound and collecting the compound from the resultant cultured product. The antitumor agent and the cell motility inhibitor comprising the compound as the active ingredient are provided. An Aspergillus sp. F7720 strain (FERM P-18198) having the ability to produce the compound is obtained.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
The invention comprises 5-aryl-2-amino-2-oxazolin-4-ones of the general formula: &lt;FORM:0907848/IV (b)/1&gt; and the non toxic acid addition salts and tautomers thereof, wherein X is a halogen atom and R1 and R2 are the same or different and are hydrogen atoms or C1-6 alkyl groups or X is a hydrogen atom and R1 and R2 are the same or different C1-6 alkyl groups and the preparation thereof (a) by condensing a 2-oxazolid-4-one of the formula &lt;FORM:0907848/IV (b)/2&gt; with an alkylating or aminating agent, wherein (i) when Y is NHR1, in which R1 is a hydrogen atom or a C1-6 alkyl group and X is aydrogen or halogen atom the alkylating agent is a C1-6 alkyl sulphate or sulphonate, the alkylation being carried out in the presence of a base (ii) when Y is -NR3R4 or SR3 in which R3 and/or R4 are hydrogen atoms or alkyl or aryl groups then the aminating agent is R1R2NH X, R1 and R2 being defined as in I or (b) by cyclizing a phenylacetic acid derivative of the general formula &lt;FORM:0907848/IV (b)/3&gt; wherein (i) K is -NH-C:Z-NR1R2 in which Z is O when Y is halogen or sulphonyloxy and Z is NH or S when Y is OH or (ii) K is NHCN and Y is OH, or (iii) K is NR3R4 or OR5 in which R3 and R4 are hydrogen atoms, alkyl or aryl groups and R5 is an alkyl or aryl group and Y is -O-C:NH-NR1R2. The starting materials for process (b) are prepared in situ from an appropriate reactive phenylacetic acid derivative and a urea, thiourea, guanidine, or cyanamide. Acyl ureas derived from urea or dialkylurea and 2-phenyl-2-haloacetyl halides, alkyl 2-phenyl-2-haloacetates, 2-phenyl-2-(p-toluenesulphonyloxy)-acetyl halides or their o-halophenyl analogues may be isolated. Ethyl o-fluoromandelate is prepared by esterification of the acid with ethanol in the presence of p-toluenesulphonic acid. Pharmaceutical compositions useful as central nervous system stimulants comprise the compounds of general formula I together with a pharmaceutical excipient and may be in the form of tablets, dragees, capsules, suppositories, liquids to be administered in drops, emulsions, suspensions, syrups, chocolate, candy and chewing gum. U.S.A. Specification 2,892,753 is referred to.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to obstetrics, and concerns the correction of antihypertensive preparations (AHP) dosage in pregnant women with arterial hypertension. It involves Doppler ultrasound of the &#34;mother-placenta-foetus&#34; system. The uteroplacental misperfusion severity is evaluated. The IA or IB severity level require the AHP dosage to be reduced by 25% as compared to the initial one, while in the II severity level, the dosage is to be reduced by 50%, and in the III severity level - by 75%. ^ EFFECT: method provides optimised antihypertensive therapy in the pregnant women with taking into account the misperfusion severity level in the &#34;mother-placenta-foetus&#34; system, and as consequence, decreased number of foetal growth inhibition cases and improvement of pregnancy terminations. ^ 5 ex
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a diagnosis marker capable of rapidly and competently judging the morbidity of live body disintegrative syndrome originated from various diseases.  &lt;P&gt;SOLUTION: This marker peptide set of live body disintegrative syndrome comprises at least one peptide being a decomposition product of proteins existing in a live body, and detected in the biological fluid of a live body disintegrative syndrome patient and that of a healthy person with a statistically significant difference. This antibody recognizes either one of peptides of the marker peptide set. This therapeutic agent of the syndrome replenishes the parent protein of the marker peptide or contains a substance which is the marker itself or simultaneously regulates the quantity or the activity of a physiologically active peptide capable of acting in the direction of healing or worsening the disease. A judging method of the stage of live body disintegrative syndrome, by detecting at least one peptide constituting the marker peptide set in the live body sample which is derived from the patient affected a basic disease to result in live body disintegrative syndrome, an evaluation method of treatment effect, and an estimation method of the abolition of the function of part/organ of a patient and/or the danger of life continuation are also invented.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
Cosmetic composition for use in treating damaged hair. The composition comprises, as the active component a methylol compound of the formula:   IN A SUITABLE COSMETIC CARRIER, IN WHICH FORMULA: X represents either an oxygen atom or a sulfur atom or an NH group; R and R&#39;&#39; are identical or different and represent either a hydrogen atom or a lower alkyl radical; and R1 and R2 represent either a methyl hydroxy group or a methyl alkoxy group, e.g. methyl alkoxy wherein the alkoxy contains up to five carbon atoms or more. Typically the methylol compound is N,N&#39;&#39;-dihydroxymethyl glyoxalurea or N,N&#39;&#39;-dihydroxymethyl glyoxalthiourea. The composition is applied at an acid pH and is advantageously made up in solid form for mixing with water or water-and-alcohol solutions when used. The compositions are used by impregnating the hair with a mixture thereof and water or water-and-alcohol solution followed by drying with heat.
A leaf extract of Fragaria ananassa Duchesne Complex having skin whitening activity is provided to inhibit the activation of tyrosinase and melanogenesis and have anticancer effect with high content of ellagic acid. A composition for skin whitening comprises 0.001~20 weight% of Fragaria ananassa Duchesne complex leaf extract. A method for manufacturing the leaf extract of Fragaria ananassa Duchesne complex comprises: a step of washing, drying, and pulverizing the leaf of Fragaria ananassa Duchesne complex; a step of extracting the pulverized leaf with 50~100% of propylene glycol solution at 50-100°C for 0.5-5 hours; a step of filtering; and a step of concentrating and removing solvent. The Fragaria ananassa Duchesne complex is a Fragaria x ananassa L. duch cv. &#39;Sulhyang&#39; from Non-san. The composition contains an ellagic acid as an ingredient.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a granulated substance of barley young leaf powder having anticavity effect.  &lt;P&gt;SOLUTION: The granulated substance of barley young leaf powder is obtained by adding water or both of water and ethanol to barley young leaf powder, kneading the mixture, subjecting the kneaded mixture to extrusion molding, and drying the molded mixture. The food is edible as it is, and excellent in palate feeling such as chewiness. The barley young leaf powder contains much dietary fibers and thereby has salivation promoting effect and also excellent anticavity effect. Such anticavity effect is enhanced by adding an anticavity component such as lactobacillus to the barley young leaf powder before granulation.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
The invention relates to composition for the treatment of the keratinous material especially keratin fiber, comprising at least one electrophilic monomer and at least one pigment and/or a filler i.e. previously treated on surface by an organic agent, where the pigment or the treated filler is different from mica covered with titanium and an organic pigment, in a medium. The invention also relates to the method of processing keratin fiber by this composition, and application of the composition on keratinous fibers. The composition of the invention obtains marked coloration even for a dark-color substrate without the need of keratin fibers&#39; degradation and without damage their cosmetic character possibly. Furthermore, coloration has shampoo fastness. The composition of the invention enabling the keratinous material obtain favorable pliability, long-lasting, shampoo fastness and uniformity. The composition of the invention have favorable stability.
The anti-carcinogen injection made by the process of the present invention is suitable for treating and preventing various kinds of malignant tumors such as liver cancer, lung cancer, thyroid cancer, prostatic cancer, rectum cancer, etc. and is especially suitable for treating the liver cancer and the lung cancer; the inhibition ratio of various kinds of malignant tumors reaches 67%. The injection uses alive hagworm as a main raw material; six kinds of Chinese herbal medicine such as rhizoma corydalis, etc. are added; the injection is prepared through fine processing; the main technological processes comprise material selection, abdomen dissection, interception, washing, decoction, cooling to obtain clear liquid, deposition, filtration, package, etc. Animal experiments demonstrate that the injection has good prevention and treatment effect on the mouse ehrlich&#39;s ascites carcinoma and the liver cancer. The present invention is anti-carcinogen injection without toxicity or side effect.
A system and method for graphically indicating patient information. The invention includes a representative image of the patient with icons to indicate or inform a health care worker of the condition of the patient. Each icon in a set of icons represents a condition available for use in describing the condition of a particular patient. Each icon is located at a predetermined position of the image in each implementation of the invention. After a user creates an image with icons selected for a particular patient, a fixed representation of the image is created. The fixed representation of the image (e.g., on a sheet of paper) is placed proximal to the patient (e.g., bedside) for visual conveyance of the patient&#39;s condition.
According to the present invention, there is provided a system and method for the collection, capture, processing, storage, and tracking of data for both electronic clinical trial and electronic source health records for purposes, based upon a single data collection instance. Upon the collection of data at a clinical trial site, the data are transmitted to a central server where it is captured as an electronic source document(s) in human readable format. The system then transmits the captured electronic source document to a trusted third-party&#39;s electronic document repository. Then, the system uses the same captured data to populate the clinical trial&#39;s electronic data capture database. The system incorporates security and encryption features to ensure that privacy information requirements are not violated. In the preferred embodiment, the electronic data capture provider for a clinical trial has no control over the server of the trusted third-party vendor, complying with regulatory requirements. Additionally, the collected data can be pushed into a clinical site&#39;s electronic health record system or any equivalent system which houses electronic data. Throughout the operation of the system, an audit trail is maintained which records information relating to all data recording, modifying, and accessing events.
A therapeutic composition and a method for the treatment of cancer by depletion of arginine without systemic complications comprising an arginine decomposing enzyme and protein breakdown inhibitors, a nitric oxide donor, a pressor peptide, and prostacyclin. The composition may further include an amino acid mixture lacking arginine, an antidote for cyanide, blood plasma or its derivatives, and/or a preparation of arginine. The arginine decomposing enzyme may modified to increase circulation half-life and can be type I liver arginase, or type II of human or animal, partially purified, or recombinant, or even bacterial origin. It may be administered as a drug or released from the patient&#39;s own tissue. Endogenous production of arginine, particularly via so-called intestinal-kidney axis, can be beneficially inhibited at several enzymatic steps, allowing for deeper reductions of circulating arginine. Different components of the composition may be administered separately, or in suitable mixtures, allowing for needed adjustments during the treatment.
Medicines against viral hepatitis B, viral hepatitis &#39;&#39;non A, non B&#39;&#39; and acquired immunodeficiency syndrome are prepared by extracting simultaneously in boiling water or aqueous medium the following parts of the following plants: Andrographis paniculata: leaves; branches; roots. Cyclea barbata: leaves. Morinda citrifolia: fruits and kernels. Merremia mammosa: tubercules. Curcuma domestica: rhizomes. Curcuma xanthorrhiza: rhizomes. The thus obtained liquid extracts can be administered orally or be used for the preparation of other medical forms. These medicines have a beneficial effect in view of the purification of the blood and elimination of infectious agents within the whole organism.
&lt;P&gt;PROBLEM TO BE SOLVED: To treat the disorders (particularly cancers) considered to be caused by abnormal immune responses.  &lt;P&gt;SOLUTION: Dendritic cells (DC) play a critical role in antigen-specific immune responses. Materials and methods are provided for treating disease states including cancer. The method includes decreasing the responsiveness to activation stimuli by diseases by stimulating dendritic cells from the host. In particular, methods are provided for treating cancer in a mammal comprising administering to the mammal an effective amount of a tumor-derived DC inhibitory factor antagonist in combination with an effective amount of a Toll-like receptor (TLR) agonist.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
Pyrrolo[2,1-b]-3-benzazepines of the formula &lt;IMAGE&gt; and their salts, e.g. cis/trans geometrical isomers, are prepared in pure form or as mixture. The substituents are defined in Claim 1. These compounds are obtained by reacting an appropriate aminopropylidene-trisubstituted phosphorane with the appropriate ketone of the formula II. The isomers, preferably the E isomer, can be obtained from the mixture of isomers by chromatographic separation. The resulting compounds can be used as skeletal muscle relaxants or sedatives. &lt;IMAGE&gt;
Thinness is a major problem at present. The invention has the object of suppressing both the appetite and the appetency. This takes place by deceiving the appropriate organs, especially sensory organs. Both the chewing and the digestion functions of the body are to abolish the appetite and the appetency by a &#34;dry run&#34;. This inhibition is further enhanced by a deviation, for example by odorous substances, especially pheromones. This edible material thus essentially comprises a chewable substance in conjunction with swelling and bulk substance as well as appetite-inhibiting, appetite-suppressing substances, vital substances and flavouring and aromatising substances with odorous substances. The following are therefore employed:   1. directly acting saturation components for subjective repletion as well as   2. indirectly acting deviation components for subjective aversion.